Sun Pharma: Q2FY23 Result Update
03-11-2022

Results

INR Cr.

Y-o-Y Growth

Comments

Revenue

10,952

13.8%

Growth was driven by market share gain in India, ramp up of global specialty sales and positive impact of currency movements

EBIT

2,957

12.4%

Margin came in at 27% (-30bps) primarily due to higher other expenses, especially selling & distribution expenses

Click here for 10 year X-ray

Key Highlights:

  • US sales grew 14% YoY (30% of revenue), Domestic Formulations grew 8.5% (10.9% ex-Covid related products) (32% of revenue), Emerging Market sales grew 6.7% YoY.
  • Specialty sales grew 27.5% YoY due to pick up in sales of Ilumya, Cequa and Winlevi
  • Gross margin expanded by 150bps YoY to 74.9% owing to better product mix, benefits from the PLI scheme and positive impact of currency movements.
  • Therapies that performed well in Domestic Formulations biz included Central Laboratory Services (CLS), Gastro, Gynaecology, Urology and Respiratory.
  • The co. launched 3 new generic products in the US Market.

Management Outlook:

  • R&D spends (4.8% of revenue this quarter) is expected to gain momentum in the coming quarters.
  • It plans to expand the field force by ~10% in FY23 for geographic expansion as well as brand focus.
  • It continues to face challenges to recruit new patients to test psoriatic arthritis indication for Ilumya.
  • The moderation in prescriptions of Winlevi is temporary and a revival is expected in coming quarters.
  • It continues to implement measures to address USFDA’s observations at its Halol facility.
Disclosure: MoneyWorks4me's employees may have exposure in the securities mentioned in the above report. For detailed disclosure click here.

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×